PBH Prestige Consumer Healthcare Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1295947 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.1%
TTM net income YoY-22.8%
TTM EPS YoY-19.8%
Revenue 3-yr CAGR1.2%
Net income 3-yr CAGR—
Margins
Gross margin52.5%
Operating margin25.0%
Net margin13.3%
FCF margin18.4%
EBITDA margin28.1%
Returns
ROE8.2%
ROA3.8%
ROIC (approx.)6.9%
Asset turnover0.29x
Leverage & solvency
Liabilities / assets58.8%
Debt / equity1.07x
Current ratio2.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.48x
Accruals ratio-1.8%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 | FY20242024-03-31 | FY20232023-03-31 | FY20222022-03-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.09B | $1.14B | $1.13B | $1.13B | $1.09B |
| Cost of revenue | $493.13M | $503.30M | $500.91M | $502.43M | $466.17M |
| Gross profit | $595.58M | $634.46M | $624.45M | $625.29M | $620.65M |
| SG&A expense | $116.45M | $108.21M | $106.15M | $107.35M | $107.46M |
| Operating income | $309.41M | $336.77M | $342.43M | -$22.41M | $329.92M |
| Interest expense | — | $1.80M | $5.20M | $4.40M | $64.29M |
| Pretax income | $257.50M | $284.19M | $276.02M | -$93.92M | $262.46M |
| Income tax | $67.19M | $69.58M | $66.69M | -$11.61M | $57.08M |
| Net income | $190.30M | $214.60M | $209.34M | -$82.31M | $205.38M |
| EBITDA | $340.68M | $366.95M | $373.10M | $10.21M | $362.01M |
| EPS (basic) | 3.93 | 4.32 | 4.21 | -1.65 | 4.09 |
| EPS (diluted) | 3.91 | 4.29 | 4.17 | -1.65 | 4.04 |
| Weighted avg. shares (diluted) | 48.72M | 50.08M | 50.18M | 49.89M | 50.84M |
| Banking | |||||
| Net interest income | -$42.34M | -$47.63M | -$67.16M | -$69.16M | -$64.29M |
| Provision for credit losses | $10.33M | $0 | $0 | — | — |
| Balance sheet | |||||
| Cash & equivalents | $63.87M | $97.88M | $46.47M | $58.49M | $27.18M |
| Receivables | $191.92M | $194.29M | $176.78M | $167.02M | $139.33M |
| Inventory | $159.13M | $147.71M | $138.72M | $162.12M | $120.34M |
| Current assets | $431.48M | $448.33M | $375.04M | $391.74M | $293.27M |
| PP&E, net | $121.69M | $74.55M | $76.51M | $70.41M | $71.30M |
| Goodwill | $581.11M | $527.42M | $527.73M | $527.55M | $578.98M |
| Intangibles | $2.30B | $2.30B | $2.32B | $2.34B | $2.70B |
| Total assets | $3.49B | $3.40B | $3.32B | $3.35B | $3.67B |
| Current liabilities | $120.92M | $106.62M | $117.05M | $160.72M | $143.42M |
| Short-term debt | $0 | — | — | — | — |
| Long-term debt | $993.95M | $992.36M | $1.13B | $1.35B | $1.48B |
| Total debt | $993.95M | $992.36M | $1.13B | $1.35B | $1.48B |
| Total liabilities | $1.61B | $1.57B | $1.66B | $1.91B | $2.09B |
| Shareholders' equity | $1.89B | $1.83B | $1.66B | $1.45B | $1.58B |
| Net debt | $930.09M | $894.47M | $1.08B | $1.29B | $1.45B |
| Cash flow statement | |||||
| Operating cash flow | $257.63M | $251.51M | $248.93M | $229.72M | $259.92M |
| Capital expenditure | $11.18M | $8.22M | $9.55M | $7.78M | $9.64M |
| Free cash flow | $246.45M | $243.29M | $239.38M | $221.93M | $250.28M |
| Investing cash flow | -$136.84M | -$17.45M | -$20.11M | -$11.58M | -$256.51M |
| Financing cash flow | -$156.06M | -$182.07M | -$241.01M | -$185.85M | -$7.57M |
| Depreciation & amortization | $31.27M | $30.17M | $30.68M | $32.62M | $32.09M |
| Stock-based compensation | $10.84M | $11.16M | $14.01M | $12.40M | $9.04M |
| Share buybacks | $156.28M | $51.51M | $25.00M | $50.00M | $0 |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.